136th ENMC International Workshop: Charcot-Marie-Tooth Disease Type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 16, Issue 6, 2006, Pages 396-402

  Reilly, M M ^a   Jonghe, P de ^b   Pareyson, D ^c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

Ascorbic acid; Charcot Marie Tooth disease; Clinical trial; Hereditary neuropathy; Peripheral Myelin Protein 22 (PMP22)

Indexed keywords

ANTIGESTAGEN; ASCORBIC ACID; ONAPRISTONE;

ARTICLE; CLINICAL FEATURE; DIARRHEA; DISABILITY; DOSE CALCULATION; DOSE RESPONSE; DRUG MEGADOSE; ELECTROPHYSIOLOGY; FOLLOW UP; GENE DUPLICATION; GENE OVEREXPRESSION; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; LATENT PERIOD; MOLECULAR GENETICS; MOTOR NERVE CONDUCTION; MOTOR PERFORMANCE; MUSCLE ACTION POTENTIAL; NETHERLANDS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SKIN BIOPSY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 33744998101     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2006.03.008     Document Type: Article

References (23)

1. Nelis E., Van Broeckhoven C., De Jonghe P., et al. Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study. Eur J Hum Genet 4 (1996) 25-33
2. Sereda M.W., Meyer zu Horste G., Suter U., Uzma N., and Nave K.A. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A). Nat Med 9 (2003) 1533-1537
3. Passage E., Norreel J.C., Noack-Fraissignes P., et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med 10 (2004) 396-401
4. Raeymaekers P., Timmerman V., Nelis E., et al. Duplication in chromosome 17p11.2 in Charcot-Marie-Tooth neuropathy type 1a (CMT 1a). The HMSN collaborative research group. Neuromuscul Disord 1 (1991) 93-97
5. Lupski J.R., de Oca-Luna R.M., Slaugenhaupt S., et al. DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell 66 (1991) 219-232
6. Sereda M., Griffiths I., Puhlhofer A., et al. A transgenic rat model of Charcot-Marie-Tooth disease. Neuron 16 (1996) 1049-1060
7. Huxley C., Passage E., Manson A., et al. Construction of a mouse model of Charcot-Marie-Tooth disease type 1A by pronuclear injection of human YAC DNA. Hum Mol Genet 5 (1996) 563-569
8. Young P., and Suter U. Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease. Brain Res Brain Res Rev 36 (2001) 213-221
9. Perea J., Robertson A., Tolmachova T., et al. Induced myelination and demyelination in a conditional mouse model of Charcot-Marie-Tooth disease type 1A. Hum Mol Genet 10 (2001) 1007-1018
10. Merkies I.S., Schmitz P.I., van der Meché F.G., Samijn J.P., van Doorn P.A., and for the inflammatory neuropathy cause and treatment (INCAT) group. Clinimetric evaluation of a new overall disability scale in immune mediated polyneuropathies. J Neurol Neurosurg Psychiatry 72 (2002) 596-601
11. Holman R., Lindeboom R., Vermeulen M., and de Haan R.J. The AMC Linear disability score project in a population requiring residential care: psychometric properties. Health Qual Life Outcomes 2 (2004) 42
12. Shy M., Blake J., Krajewski K., Fuerst D., Laura M., and Reilly M.M. CMT Neuropathy score: a valid measure of disability. Neurology 64 (2005) 1209-1214
13. Merlini L., Mazzone E., Solari A., and Morandi L. Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 26 (2002) 64-70
14. Kilmer B.D.D., McCrory M.A., Wright N.C., Rosko R.A., Kim H.R., and Aitkens S.G. Hand-held dynamometry reliability in persons with neuropathic weakness. Arch Phys Med Rehabil 78 (1997) 1364-1368
15. Hughes R., Bensa S., Willison H., et al. Inflammatory neuropathy cause and treatment (INCAT) group. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50 (2001) 195-201
16. Merkies I.S., Schmitz P.I., van der Meche F.G., and van Doorn P.A. Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory neuropathy cause and treatment (INCAT) group. Neurology 54 (2000) 943-949
17. Ware J.E., and Sherbourne C. The MOS 36-items short-form survey (SF-36): I. Conceptual framework and items selection. Med Care 30 (1992) 473-483
18. Li J., Bai Y., Ghandour K., et al. Skin biopsies in myelin-related neuropathies: bringing molecular pathology to the bedside. Brain 128 (2005) 1168-1177
19. Gallardo E., Garcia A., Combarros O., et al. Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles. Brain 129 (2006) 426-437
20. Ellegala D.B., Monteith S.J., Haynor D., Bird T.D., Goodkin R., and Kliot M. Characterization of genetically defined types of Charcot-Marie-Tooth neuropathies by using magnetic resonance neurography. J Neurosurg 102 (2005) 242-245
21. Dietary reference intakes, The National Academies Press, Washington DC, USA; 2000.
22. Levine M., Country-Cantilena C., Wang Y., et al. Vitamin C pharmakocinetics in healthy volunteers: evidence for a recommended dietary allowance. Proc Nat Acad Sci 93 (1996) 3704-3709
23. Hathcock J.N., Azzi A., Blumberg J., et al. Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr 81 (2005) 736-745